Spectral AI, Inc. (MDAI) · Nov 19, 2026 · Share issuance
$15M equity line — Up to $15M; shares priced at 97% of the lowest three-day VWAP
Spectral AI’s new equity financing preserves access to up to $15 million as commercialization begins, but adds variable-price dilution and no immediate cash.
Spectral AI is moving from BARDA-funded development into DeepView commercialization, but cash usage is rising. The company received FDA De Novo clearance for DeepView in May 2026 and is now funding follow-on development and launch activity; through September, revenue had fallen 33.4% year over year while operating cash use reached $10.5 million.
The filing refreshes financing access rather than delivering cash today. Spectral AI can sell up to $15 million of common stock to Yorkville over 24 months, but sales remain entirely at the company’s option: "The Company has the right to sell to Yorkville up to $15.0million of its shares" and "the Company is under no obligation to sell any shares of Common Stock to Yorkville under the SEPA." 〔0〕
The trade-off is expensive, variable-price dilution. Yorkville’s purchase price is set at 97% of the lowest daily VWAP across a three-day pricing period, while Nasdaq limits issuance to 6,433,767 shares—19.99% of the pre-agreement share count—unless shareholders approve more or the average price reaches at least $1.35. 〔1〕 〔2〕
This is useful liquidity optionality, not a business inflection. The facility can help fund DeepView’s commercialization and ongoing development, but it does not improve demand, reimbursement, or sales execution—and drawing it would increase dilution precisely as the company moves beyond government-funded development. The Yorkville relationship itself is not new: Spectral AI had already disclosed a 2024 SEPA, so the surprise is the refreshed structure and smaller $15 million capacity, not the financing concept.
Bottom line: Spectral AI has preserved a funding backstop during a cash-intensive commercialization transition, but only through a discounted equity line that can dilute shareholders. It modestly weakens the story because the filing addresses financing need, not operating progress, and provides no immediate proceeds.
First Advance Notice under the amended SEPA
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!